neovasc inc  home  neovasc inc cosira coronary sinusreducer for treatment ofrefractory angina positive results from the cosira clinical trial assessing theefficacy and safety of the neovasc reducer publishedin the new england journal of medicinelearn moretiara minimally invasive treatment for a common formof mitral valvedisease potential new therapeutic optionfor millions of patients learn morethis product is an investigational device onlyit is not approved in any geographyreducer a novel device for thetreatment of refractory anginapotential relief of symptoms for those suffering from persistent angina painlearn morethis device is currently only available in the eurevolutionizingadvancedheart diseasetreatmentlearn more   neovasc inc register to receive neovasc updates via emailcountryunited states of americaaaland islandsafghanistanalbaniaalgeriaamerican samoaandorraangolaanguillaantarcticaantigua and barbudaargentinaarmeniaarubaaustraliaaustriaazerbaijanbahamasbahrainbangladeshbarbadosbelarusbelgiumbelizebeninbermudabhutanboliviabosnia and herzegovinabotswanabouvet islandbrazilbritish indian ocean territorybrunei darussalambulgariaburkina fasoburundicambodiacamerooncanadacape verdecayman islandscentral african republicchadchilechinachristmas islandcocos keeling islandscolombiacomoroscongocook islandscosta ricacote divoirecroatiacubacuracaocyprusczech republicdemocratic republic of the congodenmarkdjiboutidominicadominican republiceast timorecuadoregyptel salvadorequatorial guineaeritreaestoniaethiopiafalkland islandsfaroe islandsfijifinlandfrancefrench guianafrench polynesiafrench southern territoriesgabongambiageorgiagermanyghanagibraltargreecegreenlandgrenadaguadeloupeguamguatemalaguernseyguineaguineabissauguyanahaitiheard and mc donald islandshondurashong konghungaryicelandindiaindonesiairaniraqirelandisle of manisraelitalyjamaicajapanjersey channel islandsjordankazakhstankenyakiribatikuwaitkyrgyzstanlao peoples democratic republiclatvialebanonlesotholiberialibyaliechtensteinlithuanialuxembourgmacaumacedoniamadagascarmalawimalaysiamaldivesmalimaltamarshall islandsmartiniquemauritaniamauritiusmayottemexicomicronesia federated states ofmoldova republic ofmonacomongoliamontenegromontserratmoroccomozambiquemyanmarnamibianaurunepalnetherlandsnetherlands antillesnew caledonianew zealandnicaraguanigernigerianiuenorfolk islandnorth koreanorthern mariana islandsnorwayomanpakistanpalaupalestinepanamapapua new guineaparaguayperuphilippinespitcairnpolandportugalpuerto ricoqatarrepublic of kosovoreunionromaniarussiarwandasaint kitts and nevissaint luciasaint vincent and the grenadinessamoa independentsan marinosao tome and principesaudi arabiasenegalserbiaseychellessierra leonesingaporesint maartenslovakiasloveniasolomon islandssomaliasouth africasouth georgia and the south sandwich islandssouth koreasouth sudanspainsri lankast helenast pierre and miquelonsudansurinamesvalbard and jan mayen islandsswazilandswedenswitzerlandsyriataiwantajikistantanzaniathailandtogotokelautongatrinidad and tobagotunisiaturkeyturkmenistanturks  caicos islandsturks and caicos islandstuvaluugandaukraineunited arab emiratesunited kingdomuruguayusa minor outlying islandsuzbekistanvanuatuvatican city state holy seevenezuelavietnamvirgin islands britishvirgin islands uswallis and futuna islandswestern saharayemenzambiazimbabwe neovasc inc  be part of a canadian biotech team developing prosthetic heart valves careers we rely on the expertise and enthusiasm of our employees to deliver on our promises to customers and shareholders our closeknit creative team strives for excellence in everything we do and comprises professionals that specialize in research and development product development engineering field clinical support regulatory affairs quality systems manufacturing  production quality control clinical affairs if you think you have the skills and attitude to enhance our company we want to hear from you a resume and a letter outlining how you think you can contribute to our efforts may be sent to careersneovasccom   current opportunities in new brighton mn usa   clinical safety specialist the clinical safety specialist will have primary responsibility for coordinating death and adverse event collection assessment adjudication and analysis in collaboration with other members of the clinical affairs team and ensure regulatory affairs is notified of events that require reporting in compliance with applicable regulatory standards and internal requirements if you feel you meet these requirements and those set out in the complete job description we welcome you to submit your resume and cover letter to careersneovasccom   senior regulatory affairs specialist the senior regulatory affairs specialist completes projects as assigned to obtain international regulatory approvals and ensures corporate compliance to the applicable rules and regulations if you feel you meet these requirements and those set out in the complete job description we welcome you to submit your resume and cover letter to careersneovasccom   current opportunities in vancouver bc canada   senior regulatory affairs specialist the senior regulatory affairs specialist completes projects as assigned to obtain international regulatory approvals and ensures corporate compliance to the applicable rules and regulations if you feel you meet these requirements and those set out in the complete job description we welcome you to submit your resume and cover letter to careersneovasccom   tissue technician we are currently looking for a tissue technician to work with biological tissue and ensure it is assembled and processed in accordance with the quality management system if you feel you meet these requirements and those set out in the complete job description we welcome you to submit your resume and cover letter to careersneovasccom   neovasc inc neovasc inc  neovasc tiara  neovasc inc neovasc tiara tiara is a novel transcatheter device designed to treat mitral regurgitation mr a condition that is often severe and can lead to heart failure and death neovasc is developing the tiara for the treatment of severe mr a condition that affects approximately four million patients in the us alone currently conventional surgical treatments are only appropriate for about  of these patients leaving the majority of patients untreated the tiara device is delivered through the apex of the heart to replace the mitral valve while preserving the integrity of the surrounding structures of the heart this is an investigational device only at this time and is not for sale in any geography tiara has been designed specifically to address each of the challenges listed below and meet the need for transcatheter replacement of the mitral valve rather than being adapted from an aortic valve tiara implantation is achieved through a transapical approach and does not require any hemodynamic support we invite you to register for neovasc news alerts to be apprised of tiara updates as we move through the development program challenges to treatment of the mitral valve include complex geometry of the mitral apparatus changes of the mitral apparatus throughout the cardiac cycle maintaining continuity with the sub valvular structures native d shape of the mitral valve proximity to the aortic valve and potential for left ventricular outflow tract lvot obstruction large size of the mitral valve  larger crossing profile high closing pressures left ventricular remodelling references nkomo vt et al lancet  mirabel m et al eur heart j  lamas ga circulation  grigioni f circulation  ellis sgam j cardiol  sachin s goel jacc  vol  no    neovasc inc neovasc inc  governance  neovasc inc governance neovasc’s board of directors sets high standards for the companys employees officers and directors implicit in this philosophy is the importance of sound corporate governance it is the duty of the board of directors to serve as a prudent fiduciary for shareholders and to oversee the management of the company’s business to fulfill its responsibilities and to discharge its duty the board of directors follows the procedures and standards that are set forth in these guidelines these guidelines are subject to modification from time to time as the board of directors deems appropriate in the best interests of the company or as required by applicable laws and regulations the board believes that its proper governance and effectiveness in carrying out its duties is greatly enhanced by the use of committees our board has three committees audit  strategic activities committee corporate governance  nominating committee compensation committee the board makes every effort to ensure these committees are staffed with outside directors interested parties may request information about the charters of the above committees or about our additional board policies code of ethics disclosure policy whistleblower procedures   neovasc inc neovasc inc  canadian biotech firm specializing in cardiovascular devices about neovasc neovasc inc is a specialty medical device company that develops manufactures and markets products for the rapidly growing cardiovascular marketplace our products include the tiara™ technology in development for the transcatheter treatment of mitral valve disease the neovasc reducer™ for the treatment of refractory angina a canadian biotech company headquartered in vancouver bc canada we are a publicly traded company listed on nasdaq nvcn and the toronto stock exchange tsx nvc  we invite you to register to receive neovasc news updates  by email our certifications   neovasc inc neovasc inc  clinical reports  reducer refractory angina treatment  neovasc inc clinical reports cosira clinical study the cosira coronary sinus reducer for treatment of refractory angina trial a prospective multicenter shamcontrolled randomized doubleblinded study assessing the safety and efficacy of the reducer in  patients in europe and canada trial highlights the cosira data demonstrated that patients treated with the reducer achieved a statistically significant improvement in the canadian cardiovascular society “ccs” angina grading scale scores two classes or better compared to those patients in the sham control arm pvalue   patients treated with the reducer were  times more likely to see an improvement of two classes or better in ccs score than the sham control arm the analysis also demonstrated that patients treated with the reducer showed a statistically significant improvement of one or more ccs classes compared to the sham control patients pvalue   the study also demonstrated a  technical success rate and a  procedural success rate for reducer implantation the final results from the cosira study were published in the new england journal of medicine to obtain copies from the publisher click here coronary sinus reducer stent for the treatment of chronic refractory angina pectoris a prospective openlabel multicenter safety feasibility firstinman study authors shmuel banai md shmuel ben muvhar keyur h parikh md aharon medina md horst sievert md ashok seth md jonathan tsehori md yoav paz md ami sheinfeld md gad keren md fifteenpatient study demonstrates the safety and feasibility of the coronary sinus reducer™ for patients with refractory angina who are not candidates for conventional revascularization procedures read abstract from the journal of the american college of cardiology learn more about the reducer product view   neovasc inc neovasc inc  contact  neovasc inc contact should you wish to receive neovasc news updates by email please register here please direct all other inquiries as follows general enquiries  maycrest way  richmond bc vv j canada phone  fax  infoneovasccom customer service  sales phone  ext toll free  ext in us  canada infoneovasccom investor relations chris clark cfo phone  tollfree  ext  in us  canada investorsneovasccom    neovasc inc neovasc inc  develops cardiovascular products including the neovasc reducer™ for the treatment of refractory angina the tiara™ technology in development for the transcatheter treatment of mitral valve disease and a line of advanced biological tissue products news releases the new england journal of medicine publishes positive results from clinical study of neovasc’s reducer product february th  the new england journal of medicine publishes positive results from clinical study of neovasc’s reducer product neovasc closes offering of common shares february rd  neovasccloses offering of common shares neovasc increases size and prices offering of common shares january th  neovasc increases size and prices offering of common shares neovasc announces proposed public offering of common shares january th  neovasc announces proposed public offering of common shares neovasc to ring closing bell at nasdaq january th  neovasc to ring closing bell at nasdaq neovasc announces treatment of first patient in tiarai clinical trial december st  neovasc announces treatment of first patient in tiarai clinical trial neovasc inc announces financial results for the third quarter  november th  tiara receives conditional approval from fda for early feasibility studyreducer live case completed successfully at tct  neovasc to present at three upcoming investor conferences in november november th  neovasc to present at three upcoming investor conferences in november « older news   neovasc inc neovasc inc  home  neovasc inc cosira coronary sinusreducer for treatment ofrefractory angina positive results from the cosira clinical trial assessing theefficacy and safety of the neovasc reducer publishedin the new england journal of medicinelearn moretiara minimally invasive treatment for a common formof mitral valvedisease potential new therapeutic optionfor millions of patients learn morethis product is an investigational device onlyit is not approved in any geographyreducer a novel device for thetreatment of refractory anginapotential relief of symptoms for those suffering from persistent angina painlearn morethis device is currently only available in the eurevolutionizingadvancedheart diseasetreatmentlearn more   neovasc inc register to receive neovasc updates via emailcountryunited states of americaaaland islandsafghanistanalbaniaalgeriaamerican samoaandorraangolaanguillaantarcticaantigua and barbudaargentinaarmeniaarubaaustraliaaustriaazerbaijanbahamasbahrainbangladeshbarbadosbelarusbelgiumbelizebeninbermudabhutanboliviabosnia and herzegovinabotswanabouvet islandbrazilbritish indian ocean territorybrunei darussalambulgariaburkina fasoburundicambodiacamerooncanadacape verdecayman islandscentral african republicchadchilechinachristmas islandcocos keeling islandscolombiacomoroscongocook islandscosta ricacote divoirecroatiacubacuracaocyprusczech republicdemocratic republic of the congodenmarkdjiboutidominicadominican republiceast timorecuadoregyptel salvadorequatorial guineaeritreaestoniaethiopiafalkland islandsfaroe islandsfijifinlandfrancefrench guianafrench polynesiafrench southern territoriesgabongambiageorgiagermanyghanagibraltargreecegreenlandgrenadaguadeloupeguamguatemalaguernseyguineaguineabissauguyanahaitiheard and mc donald islandshondurashong konghungaryicelandindiaindonesiairaniraqirelandisle of manisraelitalyjamaicajapanjersey channel islandsjordankazakhstankenyakiribatikuwaitkyrgyzstanlao peoples democratic republiclatvialebanonlesotholiberialibyaliechtensteinlithuanialuxembourgmacaumacedoniamadagascarmalawimalaysiamaldivesmalimaltamarshall islandsmartiniquemauritaniamauritiusmayottemexicomicronesia federated states ofmoldova republic ofmonacomongoliamontenegromontserratmoroccomozambiquemyanmarnamibianaurunepalnetherlandsnetherlands antillesnew caledonianew zealandnicaraguanigernigerianiuenorfolk islandnorth koreanorthern mariana islandsnorwayomanpakistanpalaupalestinepanamapapua new guineaparaguayperuphilippinespitcairnpolandportugalpuerto ricoqatarrepublic of kosovoreunionromaniarussiarwandasaint kitts and nevissaint luciasaint vincent and the grenadinessamoa independentsan marinosao tome and principesaudi arabiasenegalserbiaseychellessierra leonesingaporesint maartenslovakiasloveniasolomon islandssomaliasouth africasouth georgia and the south sandwich islandssouth koreasouth sudanspainsri lankast helenast pierre and miquelonsudansurinamesvalbard and jan mayen islandsswazilandswedenswitzerlandsyriataiwantajikistantanzaniathailandtogotokelautongatrinidad and tobagotunisiaturkeyturkmenistanturks  caicos islandsturks and caicos islandstuvaluugandaukraineunited arab emiratesunited kingdomuruguayusa minor outlying islandsuzbekistanvanuatuvatican city state holy seevenezuelavietnamvirgin islands britishvirgin islands uswallis and futuna islandswestern saharayemenzambiazimbabwe neovasc inc  governance  neovasc inc governance neovasc’s board of directors sets high standards for the companys employees officers and directors implicit in this philosophy is the importance of sound corporate governance it is the duty of the board of directors to serve as a prudent fiduciary for shareholders and to oversee the management of the company’s business to fulfill its responsibilities and to discharge its duty the board of directors follows the procedures and standards that are set forth in these guidelines these guidelines are subject to modification from time to time as the board of directors deems appropriate in the best interests of the company or as required by applicable laws and regulations the board believes that its proper governance and effectiveness in carrying out its duties is greatly enhanced by the use of committees our board has three committees audit  strategic activities committee corporate governance  nominating committee compensation committee the board makes every effort to ensure these committees are staffed with outside directors interested parties may request information about the charters of the above committees or about our additional board policies code of ethics disclosure policy whistleblower procedures   neovasc inc neovasc inc  canadian biotech management team specializing in heart valves management alexei marko chief executive officer  director alexei marko’s  years of experience in the medical device field spans product development sales and marketing and executive management mr marko has held management positions with neovasc’s predecessor companies since  and assumed the role of chief executive officer in  in conjunction with the company’s expansion and restructuring he is a registered professional engineer a listed inventor on issued and pending medical technology patents and has been instrumental in the development and approval of multiple medical device products mr marko has led neovasc to win multiple industry awards and has been the recipient of several individual awards including top  under  and has been named as one of canada’s top  mentors mr marko completed a bsc hons degree at queen’s university and a mscin electrical engineering at the university of british columbia specializing in medical device development christopher clark chief financial officer mr clark has almost  years finance and accounting experience in public practice and in public and private companies most recently focused in the medical device sector previous experience includes financial leadership roles with large automotive and telecom firms in which he developed deep expertise in the development and management of sophisticated financial systems a highly sought after consultant for biotechnology startups mr clark accepted the role of chief financial officer at neovasc and was instrumental in the initial and ongoing development of neovasc as a publicly traded company he received his designation as a chartered accountant from the institute of chartered accountants of england and wales and articled with kpmg before moving to canada from england in  he has an honors degree in economics from swansea university and a post graduate diploma from keble college oxford brian mcpherson chief operating officer mr mcpherson has more than  years of experience in medical device operations encompassing a unique combination of manufacturing organizational and technical management experience he was previously the operations manager and served on the board of directors for pyng medical corp and was part of the team that led the company to its first profitable year he was also a senior manager and served on the board of directors with arterial vascular engineering canada as it grew from  to  employees mr mcpherson’s responsibilities at neovasc include managing manufacturing and logistics performance productivity and cost effectiveness as well as directing all activities related to the business development distribution and sales of neovasc’s tissue products and contract manufacturing business he holds two diplomas of technology from the british columbia institute of technology the most recent in biomedical engineering   randy lane vicepresident of research and development randy lane earned a bachelor of science from mcgill university and has held senior roles at global cardiovascular device firms prior to joining neovasc mr lane was engaged for a year period in product development and manufacturing with sorin mitroflow possessing expertise in prosthetic heart valve design and testing mr lane represents canada on the iso  committee as a technical expert in heart valves and has led teams throughout the complete development program including the development of process improvements product development and regulatory testing mr lane’s tenure at neovasc commenced with the leadership of its first contract development transcatheter aortic heart valve program and he has since led its technical team to success with many of its current projects including the neovasc tiara™ the patent for which he is listed as the primary inventor vicki bebeau vice president of clinical and regulatory affairs vicki bebeau has been a leader in the planning and execution of clinical trials for more than  years fulfilling leadership roles with multinational cardiovascular device firms such as st jude medical boston scientific and medtronic having planned and directed numerous successful clinical studies of prosthetic heart valves and other cardiovascular devices in support of ide pma and post market programs to support regulatory approvals ms bebeau’s efforts have contributed to the adoption of some of the industry’s most novel devices in the united states canada europe australia and japan holding a bachelor of science in nursing from bethel college ms bebeau is a registered nurse whose specific areas of clinical research have included heart valves open heart and percutaneous vascular access and closure devices ffr oct renal denervation and hypothermia tom weber phd corporate scientist dr weber’s career spans  years and includes extensive and successful experience in biotechnology development programs from the early research stage through and including commercialization for firms such as m company elan corporation and angiotech pharmaceuticals he is highly regarded for his technical leadership specializing in product development technology transfer chemical characterization program managementproject leadership compliance enhancement technical supervision  mentoring and intellectual property developmentprotection areas of expertise include strategic approaches for technical and regulatory issues quality system design and enhancement comprehensive characterization of raw materials and finished products product performance testing and optimizationscaleup for product commercialization holding a phd in chemistry and undergraduate degrees in chemistry and physics dr weber’s successes to date include the development and characterization of new chemical entities drugconjugates biologics and numerous forms of drug delivery dr weber is a listed inventor on nine patents and has authored  publicationspresentations prof shmuel banai md medical director one of israel’s leading interventional cardiologists and a productive researcher professor shmuel banai was medical director of neovasc medical ltd one of the predecessor companies to neovasc inc where he now fulfills the role of medical director since  dr banai has been the director of interventional cardiology in the cardiology department at the tel aviv medical center tel aviv israel this unit performs more than  cardiac procedures annually including coronary valves and structural heart disease interventions carotid artery intervention rf ablations and pacemaker implantations   prior to joining tel aviv medical center professor banai was a senior interventional and clinical cardiologist and head of the clinical unit in the cardiology department at the hadassah hebrew university medical center in jerusalem before taking on the role at hebrew university medical centre he served as the director of interventional cardiology associate director general of the hospital and associate director of the department of cardiology at the bikurcholim hospital in jerusalem from  until  between and  he was a visiting postdoctoral scientist at the national heart lung and blood institute of the national institutions of health in bethesda maryland usa professor banai is an associate professor of medicine and cardiology at the hebrew university hadassah medical school and a professor of cardiology at the sackler school of medicine at the tel aviv university his main interests are vessel wall biology and physiology atherosclerosis vulnerable plaque pharmacological treatment of restenosis antithrombotic therapy and devicebased therapy for refractory angina professor banai is the author of more than  peerreviewed papers and book chapters as well as more than  abstracts and has participated in many clinical and preclinical research studies in the field of cardiology interventional cardiology and pharmacotherapy   neovasc inc neovasc inc  canadian biotech firm specializing in cardiovascular devices about neovasc neovasc inc is a specialty medical device company that develops manufactures and markets products for the rapidly growing cardiovascular marketplace our products include the tiara™ technology in development for the transcatheter treatment of mitral valve disease the neovasc reducer™ for the treatment of refractory angina a canadian biotech company headquartered in vancouver bc canada we are a publicly traded company listed on nasdaq nvcn and the toronto stock exchange tsx nvc  we invite you to register to receive neovasc news updates  by email our certifications   neovasc inc neovasc inc  neovasc tiara  neovasc inc neovasc tiara tiara is a novel transcatheter device designed to treat mitral regurgitation mr a condition that is often severe and can lead to heart failure and death neovasc is developing the tiara for the treatment of severe mr a condition that affects approximately four million patients in the us alone currently conventional surgical treatments are only appropriate for about  of these patients leaving the majority of patients untreated the tiara device is delivered through the apex of the heart to replace the mitral valve while preserving the integrity of the surrounding structures of the heart this is an investigational device only at this time and is not for sale in any geography tiara has been designed specifically to address each of the challenges listed below and meet the need for transcatheter replacement of the mitral valve rather than being adapted from an aortic valve tiara implantation is achieved through a transapical approach and does not require any hemodynamic support we invite you to register for neovasc news alerts to be apprised of tiara updates as we move through the development program challenges to treatment of the mitral valve include complex geometry of the mitral apparatus changes of the mitral apparatus throughout the cardiac cycle maintaining continuity with the sub valvular structures native d shape of the mitral valve proximity to the aortic valve and potential for left ventricular outflow tract lvot obstruction large size of the mitral valve  larger crossing profile high closing pressures left ventricular remodelling references nkomo vt et al lancet  mirabel m et al eur heart j  lamas ga circulation  grigioni f circulation  ellis sgam j cardiol  sachin s goel jacc  vol  no    neovasc inc neovasc inc  directors  neovasc inc directors paul geyer chairman paul geyer graduated with a basc in electrical engineering from the university of british columbia in  in  he founded mitroflow international inc a medical device company that developed and commercialized bovine tissue heart valves as the company’s president and ceo mr geyer grew mitroflow from a startup of nine employees and an investment of  in  to more than  employees in  when he sold the company to swiss firm sulzer medica for more than  million mitroflow now part of sorin group continues to be one of the largest medical device companies in the vancouver area since june  mr geyer has been ceo of lightintegra technology inc lightintegra has developed the thrombolux technology which is used as a point of care device to determine platelet quality for blood transfusions mr geyer served previously on the board of directors for the medical device development center mddc and medec the association representing medical device companies across canada he is an active angel investor and supporter of local technology and life sciences firms since  mr geyer has been actively participating as a member of the board of directors at science world british columbia where he took on the role as the board’s chairman from  to  paul has established a scholarship endowment at ubc for the support of students in the newly established biomedical engineering program paul is a director and active supporter of bc social venture partners an organization supporting families and youth at risk through social enterprises in  he was awarded the ubc engineering community service award in  mr geyer received the entrepreneur of the year award from the richmond bc chamber of commerce in  he was named as one of business in vancouver newspaper’s “top forty under ” an award given to honour outstanding young business people in the city of vancouver paul is an active angel investor in technology and life science companies in  paul was awarded the british columbia angel investor of the year he is an active supporter of the local angel investment community donating his time to assist local companies and investors through education programs and direct oneonone mentoring in  paul received the bc life sciences leadership award alexei marko chief executive officer and director alexei marko’s  years of experience in the medical device field spans product development sales and marketing and executive management mr marko has held management positions with neovasc’s predecessor companies since  and assumed the role of chief executive officer in  in conjunction with the company’s expansion and restructuring he is a registered professional engineer a listed inventor on issued and pending medical technology patents and has been instrumental in the development and approval of multiple medical device products mr marko completed a bsc hons degree at queen’s university and a mscin electrical engineering at the university of british columbia specializing in medical device development dr jane hsiao dr hsiao has served on the board of opko health inc since february  as vice chairman and chief technology officer since may  and as chairman of the board of safestitch medical inc formerly cellular technology services company inc since september  having served as a director of that company from april  dr hsiao served as the vice chairmantechnical affairs of ivax corporation from  to january  when teva acquired ivax dr hsiao served as ivax’s chief technical officer since  and as chairman chief executive officer and president of ivax animal health ivax’s veterinary products subsidiary since  from  until  dr hsiao served as ivax’s chief regulatory officer and assistant to the chairman dr hsiao served as chairman and president of dvm pharmaceuticals from  through  and is also a director of modigene inc a biopharmaceutical company dr hsiao is a member of the frost group llc a private investment firm based in miami florida dr hsiao also holds  of the total limited partnership interests in the peregrine ii group funds dr hsiao holds a phd from the university of illinois douglas janzen mr janzen has deep experience in the cardiovascular industry having served as the past president and ceo and director of cardiome pharma corp tsx com nasdaq crme a company that develops drugs to treat or prevent cardiovascular diseases mr janzen previously served as the company’s president and chief business officer since march  and prior to that as cfo mr janzen has served as a director on a number of public and private boards of therapeutic and device companies including sentinelle medical ico therapeutics and bradmer pharmaceuticals mr janzen also serves as the chairman of life sciences british columbia and as a director of biotech canada mr janzen also has extensive experience in corporate banking and financing within the biotechnology sector as an analyst and the head of research at loewen ondaatje mccutheon from  to  and then as managing director health sciences andpartner at sprott securities inc now cormark from  to  dr william o’neill dr o’neill was recently named as medical director of the new center for structural heart disease at henry ford hospital in detroit prior to this dr o’neill was professor and executive dean for clinical affairs division of cardiology at the leonard m miller school of medicine at the university of miami director of the division of cardiovascular disease at william beaumont hospital in royal oaks michigan and director of the cardiac catheterization laboratory at the university of michigan hospital in ann arbor and associate professor of medicine at the university of michigan medical school after earning his medical degree from wayne state university school of medicine dr o’neill went on to complete a cardiology fellowship at the university of michigan hospital the author of more than  publications dr o’neill has been listed annually in the best doctors in america since  dr o’neill is a world leader in the field of interventional cardiology and in developing new techniques to diagnose and treat obstructed coronary arteries his innovations include the mechanical rotary atherectomy technique for removing plaque from the arteries steve rubin mr rubin has served as chairman of the boards of directors of neovasc and bballoon since february  and as a director of bballoon since november  since may  mr rubin has been the executive vice president administration of opko health inc a specialty healthcare company that focuses on the commercialization and development of proprietary pharmaceuticals and instruments for the diagnosis and treatment of ophthalmologic disorders prior to that august  to september  mr rubin served as the senior vice president general counsel and secretary of ivax corporation which was acquired by teva pharmaceutical industries ltd in january  mr rubin is also a member of the frost group llc a private investment firm based in miami florida and serves on the boards of directors of dreams inc a verticallyintegrated sports products company modigene inc a biopharmaceutical company ideation acquisition corporation a special purpose acquisition company formed for the purpose of acquiring businesses in digital media longfoot communications corp a public shell company seeking to identify a merger or business combination candidate and safestitch medical inc a medical device company mr rubin holds a ba in economics from tulane university and a jd from the university of florida   neovasc inc nvcn key statistics  neovasc inc financial ratios  marketwatch bulletin investor alert tokyo markets close in currencies europe markets london markets expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close neovasc inc nasdaq nvcn go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus neovasc inc market closed  quotes are delayed by  min jul    pm nvcn quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   company description neovasc inc operates as a medical device company that develops manufactures and markets products for the rapidly growing cardiovascular device marketplace its products include the neovasc reducer for the treatment of refractory angina and the tiara technology in development for the transcathete neovasc inc operates as a medical device company that develops manufactures and markets products for the rapidly growing cardiovascular device marketplace its products include the neovasc reducer for the treatment of refractory angina and the tiara technology in development for the transcatheter treatment of mitral valve disease it operates through the following geographical segments us europe and the rest of the world the company was founded on november   and is headquartered in richmond canada valuation pe current  pe ratio with extraordinary items  price to sales ratio  enterprise value to ebitda  enterprise value to sales  efficiency revenueemployee  income per employee  receivables turnover  total asset turnover  liquidity current ratio  quick ratio  cash ratio  profitability gross margin  operating margin  pretax margin  net margin  return on assets  return on equity  return on total capital  return on invested capital  capital structure officers and executives name age officer since title mr alexei j marko   chief executive officer  director mr brian mcpherson   chief operating officer mr christopher clark   chief financial officer  secretary mr randy lane   vice presidentresearch  development dr shmuel banai   medical director insider actions – purchase – sale  – number of transactions  reply   show more comments  show more replies    are you sure you want to delete this chart delete cancel     replace the attached chart with a new chart  replace cancel post  please wait a minute before you try to comment again       report this comment i feel that this comment is spam offensive irrelevant submit comment flagged thank you your report has been sent to our moderators for review close add chart to comment cancel attach disclaimer fusion media would like to remind you that the data contained in this website is not necessarily realtime nor accurate all cfds stocks indexes futures and forex prices are not provided by exchanges but rather by market makers and so prices may not be accurate and may differ from the actual market price meaning prices are indicative and not appropriate for trading purposes therefore fusion media doesnt bear any responsibility for any trading losses you might incur as a result of using this data fusion media or anyone involved with fusion media will not accept any liability for loss or damage as a result of reliance on the information including data quotes charts and buysell signals contained within this website please be fully informed regarding the risks and costs associated with trading the financial markets it is one of the riskiest investment forms possible find a broker indices commodities forex bonds more categories tabs selectionindicescommoditiesforexbondsstocksetfscount selected applydwmmyymax sp  futures  nasdaq futures  dow   sp  vix  dax  nikkei   us dollar index  euro index  gold  silver  copper  crude oil wti  brent oil  natural gas  us cotton   us coffee c  eurusd  gbpusd  usdjpy  usdcad  audusd  usdcnh  ethusd  btcusd  us y yield  us y yield  us y yield  us y yield  us y tnote  us y tbond  euro bund  uk gilt  start trading today forexcommoditiesindicesstocks tabs selection forexcommoditiesindicesstocksbondsetfs count selected apply timeframe  min  mins  mins  mins hourly  hours daily weekly eurusd    summary strong sell moving averages buy  sell  indicators buy  sell  eurusd    summary strong sell moving averages buy  sell  indicators buy  sell  gbpusd    summary strong buy moving averages buy  sell  indicators buy  sell  usdjpy    summary strong buy moving averages buy  sell  indicators buy  sell  audusd    summary sell moving averages buy  sell  indicators buy  sell  usdcad    summary neutral moving averages buy  sell  indicators buy  sell  eurjpy    summary strong buy moving averages buy  sell  indicators buy  sell  eurchf    summary strong sell moving averages buy  sell  indicators buy  sell  gold futures  summary moving averages buy sell indicators buy sell silver futures  summary moving averages buy sell indicators buy sell copper futures  summary moving averages buy sell indicators buy sell crude oil wti futures  summary moving averages buy sell indicators buy sell brent oil futures  summary moving averages buy sell indicators buy sell natural gas futures  summary moving averages buy sell indicators buy sell us coffee c futures  summary moving averages buy sell indicators buy sell dow jones industrial averag  summary moving averages buy sell indicators buy sell nasdaq   summary moving averages buy sell indicators buy sell sp   summary moving averages buy sell indicators buy sell dax  summary moving averages buy sell indicators buy sell ftse   summary moving averages buy sell indicators buy sell cac   summary moving averages buy sell indicators buy sell nikkei   summary moving averages buy sell indicators buy sell apple inc  summary moving averages buy sell indicators buy sell alphabet inc class a  summary moving averages buy sell indicators buy sell bank of america corp  summary moving averages buy sell indicators buy sell jpmorgan chase  co  summary moving averages buy sell indicators buy sell exxon mobil corporation  summary moving averages buy sell indicators buy sell bp plc  summary moving averages buy sell indicators buy sell deutsche bank ag na on  summary moving averages buy sell indicators buy sell us year  summary moving averages buy sell indicators buy sell us year  summary moving averages buy sell indicators buy sell us year  summary moving averages buy sell indicators buy sell us year  summary moving averages buy sell indicators buy sell euro bund futures  summary moving averages buy sell indicators buy sell us  year tnote futures  summary moving averages buy sell indicators buy sell japan government bond futur  summary moving averages buy sell indicators buy sell uk gilt futures  summary moving averages buy sell indicators buy sell spdr dow jones industrial a  summary moving averages buy sell indicators buy sell ishares russell  growth  summary moving averages buy sell indicators buy sell ishares russell   summary moving averages buy sell indicators buy sell powershares qqq trust serie  summary moving averages buy sell indicators buy sell spdr sp   summary moving averages buy sell indicators buy sell proshares ultrashort sp  summary moving averages buy sell indicators buy sell proshares ultrashort qqq  summary moving averages buy sell indicators buy sell     eurusd  strong sell       gbpusd  strong buy       usdjpy  strong buy       audusd  sell       usdcad  neutral       eurjpy  strong buy       eurchf  strong sell       gold       silver       copper       crude oil wti       brent oil       natural gas       us coffee c       dow        nasdaq        sp        dax       ftse        cac        nikkei        apple       alphabet a       bank of america       jpmorgan       exxon mobil       bp       deutsche bank ag   start trading today recent quotes namepricechgchg   nvcn  add to watchlist add to watchlist add to watchlist max  select where to add the results added successfully create portfolio apply create close   market movers most active gainers  losers    name last chg  vol     amd   m     t   m     fb   m     nvda   m     aapl   m     ba   m     amzn   m     name last chg  vol     ba   m     t   m     biib   m     amp   m     r   m     ea   m     bbby   m     name last chg  vol     akam   m     uhs   m     rhi   m     jnpr   m     glw   m     wynn   m     nue   m   promotions should you try trading new markets nadex webinars identify sell and buy market areas tuesday august    pm edt does your trading edge suck lets fix it thursday august    pm edt intraday indicator pivot point daily formula tuesday august    pm edt neurolinguistics programming  trading psychology tuesday august    pm edt sign up for free and get realtime alerts advanced portfolio features personalized charts fullysynced app continue with facebook continue with google or sign up with email nvc stock quote  neovasc inc  bloomberg markets error could not add to watchlist x  watchlist neovasc inc nvccn ticker change nvccn has changed to a new ticker symbol cad volume  previous close  before its here its on the bloomberg terminal learn more volume  previous close  current pe ratio ttm  earnings per share cad ttm  market cap cad  shares outstanding  pricesales ttm  dividend indicated gross yield  sector health care  price change  industry health care equipment  services  price change  related videos there are currently no related videos for this ticker please check back later company news press releases there are currently no news stories for this ticker please check back later  neovasc announces tsx symbol change to nvcn there are currently no press releases for this ticker please check back later profile neovasc inc develops and markets vascular devices address suite  mayfield placerichmond bc vv ecanada phone  website wwwmedicalventurescom executives board members alexei marko chief executive officer christopher john clark chris cfosecretaryir brian mcpherson chief operating officer vicki bebeau vpclinical  regulatory affairs randy lane vpresearch  development show more neovasc inc nvc  product pipeline analysis  update about us solutions resources ebookswhite papers slideshares videos blog contact us register log in my account logout browse research my cart menu   close   x browse about us solutions resources contact us log out register log in life sciences»medical devices»medical devices company reports neovasc inc nvc  product pipeline analysis  update lowest prices guaranteed length publisher published date sku from   pages globaldata june  gbdt lowest prices guaranteed price from  length  pages publisher globaldata published date june  sku gbdt table of contents close window table of contents neovasc inc nvc  product pipeline analysis  update printer format globaldata neovasc inc company snapshot neovasc inc company overview neovasc inc pipeline products and clinical trials overview neovasc inc – pipeline analysis overview key facts neovasc inc  major products and services neovasc inc pipeline products by development stage neovasc inc clinical trials by trial status neovasc inc pipeline products overview aortoostial stent delivery system aortoostial stent delivery system product overview coronary bifurcation stent delivery system coronary bifurcation stent delivery system product overview neovasc reducer neovasc reducer product overview neovasc reducer clinical trial ostial balloon ostial balloon product overview ostial flare ostial flare product overview tiara transcatheter mitral valve tiara transcatheter mitral valve product overview tiara transcatheter mitral valve clinical trial neovasc inc  key competitors neovasc inc  key employees neovasc inc  locations and subsidiaries head office other locations  subsidiaries recent developments neovasc inc recent developments may   neovasc announces jury verdict in litigation brought by cardiaq apr   neovasc reports first quarter results for  mar   neovasc announces results for the fourth quarter and fiscal year  jan   neovasc receives fda approval to add mm valve size to the tiarai clinical trial nov   neovasc reports results for the third quarter of  oct   neovasc tiara featured in live case session at tct  scientific symposium aug   neovasc reports results for the second quarter of  may   neovasc reports results for the first quarter of  mar   neovasc announces results for the fourth quarter and full year ended  mar   neovasc launches reducer in select european countries appendix about globaldata contact us disclaimer list of tablesneovasc inc pipeline products and clinical trials overview neovasc inc pipeline products by equipment type neovasc inc pipeline products by indication neovasc inc clinical trials by trial status neovasc inc key facts neovasc inc major products and services neovasc inc number of pipeline products by development stage neovasc inc pipeline products summary by development stage neovasc inc clinical trials by trial status neovasc inc clinical trials summary aortoostial stent delivery system  product status aortoostial stent delivery system  product description coronary bifurcation stent delivery system  product status coronary bifurcation stent delivery system  product description neovasc reducer  product status neovasc reducer  product description neovasc reducer  reduceri an observational study of the neovasc reducer system neovasc reducer  use of the neovasc coronary sinus reducer system for the treatment of refractory angina pectoris in patients with angina class  who are not candidates for revascularization ostial balloon  product status ostial balloon  product description ostial flare  product status ostial flare  product description tiara transcatheter mitral valve  product status tiara transcatheter mitral valve  product description tiara transcatheter mitral valve  early feasibility study of the neovasc tiara mitral transcatheter heart valve with the tiara transapical delivery system neovasc inc key employees neovasc inc subsidiaries list of figuresneovasc inc pipeline products by equipment type neovasc inc pipeline products by development stage neovasc inc clinical trials by trial status description close window description neovasc inc nvc  product pipeline analysis  update printer format globaldata summaryneovasc inc neovasc is a medical device company that develops manufactures and sells products for cardiovascular disease the company offers products such as tiara reducer and tissue products its tiara is a novel transcatheter device that is designed for treating mitral regurgitation mr a condition that is often severe and can lead to heart failure and death neovasc biological tissue products are used as components in thirdparty medical products that include transcatheter heart valves the company’s reducer is used for the treating refractory angina neovasc is headquartered in richmond british columbia canadathis report is a source for data analysis and actionable intelligence on the company’s portfolio of pipeline products the report provides key information about the company its major products and brands the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantagescopethe report reviews detailed company profile with information on business description key company facts major products and services key competitors key employees locations and subsidiaries and recent developmentsthe report analyzes all pipeline products in development for the company neovasc incthe report provides pipeline analysis on all pipeline products of the company by equipment type by indication by development stage and by trial statusthe report covers detailed information on each pipeline product with information on pipeline territory stage of development device class regulatory path indications applications and estimated launch datethe report provides detailed description of products in development technical specification and functionsthe report also covers ongoing clinical trials wherever applicable with information on trial name trial objective sponsor trial design  trial status and phase estimated start and end datereasons to buydevelop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscapedesign and develop your product development marketing and sales strategies by understanding the competitor portfolioto formulate effective research  development strategiesdevelop marketentry and market expansion strategiesexploit inlicensing and outlicensing opportunities by identifying products most likely to ensure a robust returnplan mergers and acquisitions effectively by identifying key players of the most promising pipeline identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantagedevelop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials stage and of development etcidentify understand and capitalize the next highvalue products that your competitor would add in its portfolio search inside this report close window search inside this report download sample online download  purchase site license  purchase global site license  purchase   research assistance us  intl  download our ebook how to succeed using market research learn how to effectively navigate the market research process to help guide your organization on the journey to success download ebook share this report other tasks printer format order by fax currency converter medical devices market research reports  medical devices industry analysis  marketresearchcom about us solutions resources ebookswhite papers slideshares videos blog contact us register log in my account logout browse research my cart menu   close   x browse about us solutions resources contact us log out register log in market research » life sciences medical devices market research reports  industry analysis medical devices are durable and disposable in nature these devices can be used for a wide variety of conditions for surgical procedures home health care clinical settings or in the medical office setting a medical device is an instrument apparatus implant in vitro reagent or anything similar which can be used to diagnose prevent or treat a disease within the body it can be as simple as a tongue depressor medical thermometer or disposable gloves it can also be as complex as a computer which can assist in medical testing an implant like a stent or a prosthesis globally the medical device market is over  billion medical devices are classified in one of three regulatory classes the classification is dependent on the intended use of the device and indications for use the us accounts for approximately  of the global medical device market china japan russia and brazil have the most stringent regulatory compliance for medical devices research can be found within market research industry reports which will further outline economic industry trends device regulation globally and challenges facing medical device leaders show more show less filter your search filter your search aesthetic devices  cosmetic surgery  anesthesia  blood  cardiac rhythm management  cardiovascular devices  catheters  country overviews  critical care  dental equipment  diabetes  dialysis  disposables  drug delivery systems  durable medical equipment  electronics  endoscopy  ent  equipment  supplies  general medical devices  gynecological devices  home health  implantable devices  information technology  infusion products  manufacturing  packaging  materials science  medical devices  medical devices company reports  medical laser  minimally invasive surgery  needles syringes iv access  neurology devices  ophthalmic devices  orthopedics  patient monitoring  regulation  respiratory devices  stents  sterilization equipment  surgical equipment  urology  virtual reality  wearable medical devices  wound care  global  asia  europe  north america  south america  oceania  africa  middle east  caribbean  central america  research assistance us  intl  join alert me now receive biweekly email alerts on new research sign up find out more on our blog medical devices industry research  market reports sort by title az title za price lowtohigh price hightolow date date older first refine your search close window refine your search title publisher keyword priceusd to date any date last month last  months last  months last year last  years region all regions africa    algeria    angola    benin    botswana    burkina faso    burundi    cameroon    cape verde    central african republic    chad    comoros    the congo    the congo    cote divoire    djibouti    egypt    equatorial guinea    eritrea    ethiopia    gabon    the gambia    ghana    guinea    guineabissau    kenya    lesotho    liberia    libya    madagascar    malawi    mali    mauritania    mauritius    mayotte    morocco    mozambique    namibia    niger    nigeria    reunion    rwanda    sao tome and principe    senegal    seychelles    sierra leone    somalia    south africa    south sudan    sudan    swaziland    tanzania    togo    tunisia    uganda    western sahara    zambia    zimbabwe asia    afghanistan    armenia    azerbaijan    bangladesh    bhutan    brunei    cambodia    china    cocos keeling islands    east timor    georgia    hong kong    india    indonesia    japan    kazakhstan    kyrgyzstan    laos    macau    malaysia    maldives    mongolia    myanmar    nepal    north korea    pakistan    papua new guinea    philippines    russia    singapore    south korea    sri lanka    taiwan    tajikistan    thailand    turkey    turkmenistan    uzbekistan    vietnam caribbean    anguilla    antigua and barbuda    aruba    the bahamas    barbados    british virgin islands    cayman islands    cuba    curacao    dominica    dominican republic    grenada    guadeloupe    haiti    jamaica    martinique    montserrat    netherlands antilles    puerto rico    saint kitts and nevis    saint lucia    saint vincent and the grenadines    sint maarten saint maarten    trinidad and tobago    turks and caicos islands    virgin islands central america    belize    costa rica    el salvador    guatemala    honduras    nicaragua    panama europe    albania    andorra    austria    belarus    belgium    bosnia and herzegovina    bulgaria    croatia    czech republic    denmark    estonia    faroe islands    finland    france    germany    gibraltar    greece    guernsey    hungary    iceland    ireland    isle of man    italy    jersey    kosovo    latvia    liechtenstein    lithuania    luxembourg    macedonia    malta    moldova    monaco    netherlands    norway    poland    portugal    romania    san marino    scotland    serbia and montenegro    slovakia    slovenia    spain    sweden    switzerland    ukraine    united kingdom global middle east    bahrain    cyprus    gaza strip    iran    iraq    israel    jordan    kuwait    lebanon    oman    palestinian territories    qatar    saudi arabia    syria    united arab emirates    yemen north america    bermuda    canada    greenland    mexico    united states oceania    american samoa    australia    cook islands    fiji    french polynesia    guam    kiribati    marshall islands    micronesia federated states of    nauru    new caledonia    new zealand    niue    norfolk island    northern mariana islands    palau    samoa    solomon islands    tonga    tuvalu    vanuatu south america    argentina    bolivia    brazil    chile    colombia    ecuador    falkland islands    french guiana    guyana    paraguay    peru    suriname    uruguay    venezuela search global medical aesthetics industry injectables energybased devices cosmeceuticals cosmetic surgery facial aesthetics implants cosmetic tourism market analysis  forecast to  aug    usd  cosmetic surgery facial aesthetics implants cosmetic tourism market analysis  forecast to  published august  is a most comprehensive analysis on this vertically growing market this detailed report provides strategic business development information and  read more urology devices global market jul    usd  devices due to advantages such as fewer incisions faster recovery rate and less hospital stays compared to open surgical intervention present trend in this market is development and usage of nextgeneration urology devices like laser  read more wound closure and advanced wound care global market – forecast to  jul    usd  edges of the tissues together or by directly acting on the wounds for better healing devices such as sutures strips sealants and adhesives clips staples energy based devices haemostats and skin grafts are used to  read more asiapacific orthobiologics market forecast  jul    usd  for the market study the base year considered is  growing need for orthobiologics products in the region is up surging the growth of the asiapacific orthobiologics market market insights the asia pacific orthobiologics market  read more global flexible endoscopes market  jul    usd  endoscopes are used in diagnosis and treatment flexible endoscopes are relatively safe and are widely used in the fields of gastrointestinal gynecology ear nose and throat ent urology and laparoscopy flexible endoscopes market is driven  read more europe orthobiologics market forecast  jul    usd  base year considered for the market study is  development of technology in european countries is the primitive factor influencing the growth of the orthobilogics market in europe region market insights the europe orthobiologics market  read more north america orthobiologics market forecast  jul    usd  forecast period the base year deliberated for the study of the orthobiologics market is  the rise in the orthobiologics material and increasing demand for spinal fusion surgeries are driving the orthobiologics market in north  read more global orthobiologics market forecast  jul    usd  a cacr of  between  the base year considered for the market study is  the forecast period is  evolvement in orthobiologics has led to the development of tissue regeneration products and bone  read more global dental surgical equipment market  jul    usd  of the oral and maxillofacial region or damage due to any injury or defect involving soft and hard tissues it can be as simple as a tooth extraction or as complex as a dental implant  read more global ostomy drainage bags market  jul    usd  or any other cell debris ostomy surgeries in hospitals and other healthcare facilities increase the demand for ostomy drainage bags among inpatients inpatients who may have undergone ostomies and have fresh stomas require their drainage  read more global dental implant and prosthetics market forecast  jul    usd  revenue generated by the market is expected to increase from  million in  to  million by  the major factors driving the growth of the market are the increasing incidences of dental caries  read more global analgesic infusion pumps market  jul    usd  such as cerebral palsy spinal cord injury sci cancer sickle cell anemia and medical conditions like labor pain accident and trauma postsurgical pain and trigger pain can be relieved by analgesic infusion pumps technavio’s analysts  read more the global neurostimulation device market forecast  jul    usd  of  its net worth is estimated to rise up to  million by the end of  the fact that these devices aid in the therapeutic activation for many neurological diseases is majorly driving  read more global portable medical equipment market  jul    usd  includes patient monitoring devices medical imaging devices insulin pumps and hearing aids they are designed to monitor and treat the disorders at an earlier stage the advent of various smart technologies and wireless capabilities makes  read more europe medical devices report q  jul    usd  growth driven by robust fixed investment the six main product areas will record mid singledigitcagrs in weighted local currency terms making europe the slowest growing region in the globalmedical device market due to local currency  read more global breastfeeding supplies market  jul    usd  these supplies may also be used to stimulate lactation in mothers with irregular milk flow the global breastfeeding supplies market is expected to witness a significant growth during the forecast period due to multiple drivers  read more global orthodontic equipment and consumables market  jul    usd  harder to keep clean and are always at risk of being lost early because of tooth decay and periodontal diseases orthodontic treatment provides multiple benefits that include a healthier mouth a more pleasing appearance and  read more subsaharan africa medical devices report q  jul    usd  for most countries including south africawhich dominates the market the market will remain reliant on imports and international aid and fundingtherefore multinationals will continue to strengthen their presence overall the main six product segmentswill record  read more latin america medical devices report q  jul    usd  continue tobe the best performer despite threats posed by trade negotiations particularly between mexico and the usthe mercosur region will be driven by brazil but hindered by market restrictions in venezuela we have revised our  read more middle east and north africa medical devices report q  jul    usd  growth due to macroeconomic imbalancesderived from lower oil prices particularly in gcc markets despite its slowdown saudi arabia willcontinue to lead the gcc market while iran will spearhead the nongcc market the uae will remain  read more asia medical devices report q  jul    usd  aslightly weaker outlook for india where growth rates will moderate reflecting an increasingly competitiveoperating environment growth from increased patient volumes due to expanding healthcaresystems ageing demographics and the rising incidence of chronic diseases will be  read more global bare metal stents market  jul    usd  alloy or other highgrade metals the structure of a bms looks like a metallic coil or a tubular mesh the devices differ from each other with respect to composition delivery system and architectural design they  read more contact lenses and solutions in china jul    usd  to the convenience these lenses provide and the rise of internet retailers selling contact lenses online with many brands concentrating their marketing efforts on cultivating the usage of contact lenses in china the awareness of  read more global radio frequency beauty equipment market insights opportunity analysis market shares and forecast  –  jul    usd  firming fat burning whiten and tenderize problem areas weight loss etc technical advancement in medical equipment provides its operators facility to administrate ir infrared laser treatments rf radio frequency and dpc dynamic pulse control by  read more medical  dental instrument manufacturing in the uk  industry market research report jul    usd  dentures and orthodontic appliances the industry also includes firms that manufacture medical and dental furniture where the additional specific functions determine the purpose of the product such as dentists’ chairs with builtin hydraulic functions this  read more  prev           next  start new browse consumer goods food  beverage heavy industry life sciences marketing  market research public sector service industries technology  media company reports reports by country view all market areas view all publishers